title: Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
authors.affiliation: Institute for Innovative Cancer Research, Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
authors.forename: Jung Jin
authors.initials: JJ
authors.lastname: Hwang
authors.forename: Yong Sook
authors.initials: YS
authors.lastname: Kim
authors.forename: Mi Joung
authors.initials: MJ
authors.lastname: Kim
authors.forename: Dong Eun
authors.initials: DE
authors.lastname: Kim
authors.forename: In Gab
authors.initials: IG
authors.lastname: Jeong
authors.forename: Choung-Soo
authors.initials: CS
authors.lastname: Kim
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D000077143:Docetaxel; D004357:Drug Synergism; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects*; D043823:Taxoids / Q000627:therapeutic use*; D014404:Tubulin / Q000187:drug effects*; D014407:Tumor Cells, Cultured
chemical_list: D056572:Histone Deacetylase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel